Nvidia's sub-$350 GPU is now the most popular card on Steam
Nvidia's RTX 4060 has officially become the most widely used graphics card among gamers on Steam, thanks to its affordable price and solid performance for 1080p gaming. According to the latest Steam Hardware and Software Survey, the budget-friendly GPU has steadily gained traction since its mid-2023 launch, appealing to casual gamers, esports players, and budget-conscious PC builders.
For years, older budget GPUs like the GTX 1650 and RTX 3060 dominated Steam's charts. However, the RTX 4060 has now surpassed both, securing the top position with an 8.57% market share in February 2025. Its rise can be attributed to competitive pricing (around $300-$350), low power consumption, and modern gaming features like DLSS 3 and ray tracing support.
Compared to its predecessor, the RTX 3060, the RTX 4060 offers improvements in ray tracing, DLSS 3 frame generation, and overall efficiency. While some criticized its 8GB VRAM and narrower memory bus, it remains a solid choice for 1080p gaming, which aligns with the majority of Steam users' setups. At the time of writing, the RTX 4060 is available anywhere from $300 to $350, which is similar to the RTX 3060.
The RTX 3060, previously a dominant choice, now holds 6.87% of the market, reflecting a 1.67% increase from the previous month. The RTX 4060 Ti has also seen significant growth, rising by 3.11% to reach a 6.56% share. Similarly, the RTX 4070 experienced a 2.54% increase, bringing its total to 5.43%.
The latest survey results highlight Nvidia's overwhelming control of the PC gaming GPU market. The company occupies nearly all of the top spots, with AMD and Intel struggling to make significant gains in the consumer segment. Even as Nvidia moves forward with its RTX 50-series launch later this year, the affordability and accessibility of the RTX 4060 keep it relevant for budget-conscious gamers.
As newer graphics cards hit the market, including the RTX 50-series and AMD's Radeon 9000 range, it will be interesting to see if the RTX 4060 can maintain its lead or if another mid-range option will dethrone it in the coming months.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Wall Street Journal
26 minutes ago
- Wall Street Journal
Don't Buy the Top Stock
U.K. Prime Minister Keir Starmer and Nvidia CEO Jensen Huang on stage Monday at London Tech Week's opening event. (Tolga Akmen/EPA-EFE/shutterstock/Shutterstock)
Yahoo
an hour ago
- Yahoo
ABRDN INCOME CREDIT STRATEGIES FUND 5.25% SERIES A PERPETUAL PREFERRED SHARES DECLARE QUARTERLY DIVIDEND
PHILADELPHIA, June 10, 2025 /PRNewswire/ -- The Board of Trustees of abrdn Income Credit Strategies Fund (the "Fund"), has declared a cash distribution of $0.328125 per share of the Fund's 5.250% Series A Perpetual Preferred Shares (NYSE: ACP PRA) ("Series A Preferred Shares"). The distribution is payable on June 30, 2025, to holders of Series A Preferred Shares of record on June 20, 2025 (ex-dividend date June 20, 2025). The Series A Preferred Shares trade on the NYSE under the symbol "ACP PRA", are rated "A2" by Moody's Investors Service and have an annual dividend rate of $1.3125 per share. The Series A Preferred Shares were issued on May 10, 2021, at $25.00 per share and pay distributions quarterly. Distributions may be paid from sources of income other than ordinary income, such as net realized short-term capital gains, net realized long-term capital gains and return of capital. The actual amounts and sources of the amounts for tax reporting purposes will depend upon the Fund's investment experience during the remainder of its fiscal year and may be subject to changes based on tax regulations. In January 2026, a Form 1099-DIV will be sent to shareholders, which will state the amount and composition of distributions and provide information with respect to their appropriate tax treatment for the 2025 calendar year. You should not draw any conclusions about the Fund's investment performance from the amount of this distribution. Aberdeen Investments Global is the trade name of Aberdeen's investments business, herein referred to as "Aberdeen Investments" or "Aberdeen". In the United States, Aberdeen Investments refers to the following affiliated, registered investment advisers: abrdn Inc., abrdn Investments Limited, and abrdn Asia Limited. Closed-end funds are traded on the secondary market through one of the stock exchanges. A Fund's investment return and principal value will fluctuate so that an investor's shares may be worth more or less than the original cost. Shares of closed-end funds may trade above (a premium) or below (a discount) the net asset value (NAV) of the fund's portfolio. There is no assurance that a Fund will achieve its investment objective. Past performance does not guarantee future results. View original content to download multimedia: SOURCE abrdn Income Credit Strategies Fund 5.25% Series A Perpetual Preferred Shares
Yahoo
an hour ago
- Yahoo
Nuwellis Announces Closing of $5.0 Million Underwritten Public Offering Including Full Exercise of Overallotment Option
MINNEAPOLIS, June 10, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) ('Nuwellis' or the 'Company'), a commercial-stage medical device company dedicated to transforming care for fluid overload patients, today announced the closing of a public offering of 2,580,667 shares of its common stock ('Common Stock'), pre-funded warrants to purchase 14,085,998 shares of Common Stock, in each case with accompanying Series A Warrants to purchase up to 49,999,995 shares of Common Stock and Series B Warrants to purchase up to 16,666,665 shares of Common Stock with gross proceeds of approximately $5.0 million, which includes the full exercise of the underwriter's over-allotment option to purchase additional shares and warrants. The public offering price per share of Common Stock and accompanying warrants is $0.30 per share and accompanying warrants, and the public offering price per pre-funded warrant and accompanying warrants is $0.2999 per pre-funded warrant and accompanying warrants. Each pre-funded warrant has an exercise price of $0.0001 per pre-funded warrant, and is immediately exercisable until such pre-funded warrant is exercised in full. Each of the Series A Warrants and Series B Warrants has an exercise price of $0.30, and will be exercisable for a period of five years following the receipt of stockholder approval, as required by the applicable rules and regulations of Nasdaq. The Series A Warrants contain a one-time reset of the exercise price in the event that the Company implements a reverse stock split to the greater of: (i) 20% of the combined public offering price per share of Common Stock and accompanying warrants in this offering and (ii) the lowest daily volume weighted average price for the five trading days immediately following the date of the implementation of a reverse stock split. The Series B Warrants include a zero cash exercise option allowing holders of a Series B Warrant the right to receive, without payment of any additional cash to the Company, an aggregate number of shares equal to the number of shares of Common Stock that would be issuable upon a cash exercise of such Series B Warrant. Ladenburg Thalmann & Co. Inc. acted as sole book-running manager in connection with the offering. The securities described above are being offered pursuant to a registration statement on Form S-1 (File No. 333-287663) that was declared effective by the U.S. Securities and Exchange Commission ('SEC'), on June 9, 2025. Electronic copies of the final prospectus supplement may be obtained on the SEC's website at or by contacting Ladenburg Thalmann & Co. Inc., Prospectus Department, 640 Fifth Avenue, 4th Floor, New York, New York 10019 or by email at prospectus@ This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sales of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. The offering is being made solely by means of a prospectus. A final prospectus relating to this offering was filed by Nuwellis with the SEC. Forward-Looking Statements Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the receipt of stockholder approval to permit the exercise of the Series A Warrants and Series B Warrants, the satisfaction of customary closing conditions related to the offering and the amount and expected use of the net proceeds from the offering. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Forward-looking statements are often identified by terms such as 'believe,' 'continue,' 'intends to,' 'expect,' 'will,' 'goal,' 'aim to' and similar expressions. Such forward-looking statements include, among others, statements regarding the Company's anticipated closing of the public offering. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our ability to execute on our commercialization strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Nuwellis does not assume any obligation to publicly update or revise any forward-looking statements, whether due to new information, future events or otherwise. For further information, please contact: INVESTORS:Robert ScottChief Financial Officer, Nuwellisir@ MEDIA CONTACT:Leah McMullenDirector of Communications, Source:Nuwellis in to access your portfolio
